Glythera Limited is a biotechnology company specializing in the development of platform technologies for next generation biotherapeutics. We have 2 core programmes:
- PermaLink™ - a novel, stable, highly cysteine-specific conjugation platform for antibody drug conjugates (ADCs)
PermaLink™ is associated with enhanced anti-tumour activity in vivo vs maleimide in comparative ADC models. It is suitable for cleavable and non-cleavable systems
- PermaCarb™ - a novel sialylation correction platform which can (i) improve bioavailability & enhance product performance and (ii) remove the issue of sialic acid contamination. It is particularly appropriate for the development of biobetters and biosimilars
PermaCarb™ has been validated vs several biotherapeutics, including FSH and etanercept
Based in the NE of England, Glythera has dedicated bioprocessing and chemistry laboratories enabling us to conduct in-house evaluations for our partners to progress applications of PermaLink™ and PermaCarb™ technologies.
We are seeking license collaborations for PermaLink™ and out-license partners for PermaCarb™